GlassScriptPhysician profile
Tobias Brown
NPI 1568122083
$4,360.18
in general payments reported to CMS, 2019-2025
21 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $882 · 2024: $952 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,169.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,919.88 | 2022-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $1,048.86 | 2023-2025 | Biktarvy |
| Neurocrine Biosciences, INC. | $243.45 | 2024-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $231.36 | 2023-2025 | Pifeltro, Delstrigo, Capvaxive |
| Emd Serono, INC. | $226.75 | 2023-2025 | Serostim |
| Lilly USA, LLC | $140.73 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Hologic Sales and Service, LLC | $81.17 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Novo Nordisk INC | $74.42 | 2024-2025 | Wegovy |
| Abbvie INC. | $71.91 | 2024-2025 | |
| Napo Pharmaceuticals INC | $64.81 | 2025 | Mytesi |
| Janssen Biotech, INC. | $37.10 | 2023 | Symtuza |
| Bausch Health US, LLC | $26.34 | 2025 | Aplenzin |
| Amgen INC. | $25.22 | 2025 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $24.30 | 2024 | Rexulti, Abilify Maintena |
| Theratechnologies INC. | $24.27 | 2023 | Egrifta, Trogarzo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $24.16 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $22.73 | 2025 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $20.09 | 2025 | Breztri |
| Exact Sciences Corporation | $19.53 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $16.55 | 2025 | Contrave |
| Axsome Therapeutics, INC. | $16.55 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobias Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.